Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
kidney cancer
Pharma
Merck’s Welireg combo nabs FDA nod to expand kidney cancer reach
Analysts have projected rapid uptake for Welireg in second-line kidney cancer based on data from a phase 3 trial and doctors’ feedback.
Angus Liu
Sep 25, 2026 11:30am
Merck's Welireg surprisingly fails in first-line kidney cancer
Apr 21, 2026 10:00am
Merck's Welireg combos deliver 1-2 punch to kidney cancer
Feb 28, 2026 10:00am
Eisai’s Kompass points the way to kidney cancer support
Feb 26, 2026 11:45am
Exelixis aims to be a top 5 solid tumor drugmaker in the US: CEO
Jan 16, 2026 1:00pm
Welireg's RCC wins could pad Merck's post-Keytruda sales
Oct 28, 2025 3:00pm
